Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chugai
Pharma
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Three Chinese obesity assets are featured in Verdiva's $410 million debut. Experts analyzed the buyout prospects of Legend and BeiGene. Plus more.
Angus Liu
Jan 10, 2025 9:00am
Gilead leads Asian patient groups' drugmaker reputation rankings
Sep 25, 2024 10:40am
Enspryng falls short of Roche's expectations in myasthenia gravis
Mar 21, 2024 11:28am
FDA oncology chief, Senate bill, Insilico—Fierce Pharma Asia
Apr 1, 2022 9:35am
Eisai-Biogen, US delisting, Zai Lab and more
Mar 18, 2022 9:10am
AstraZeneca pays Roche $775M to settle Ultomiris patent brawl
Mar 17, 2022 9:40am
